The weekly litigation news digest is live. Subscribe now

IP Verse

Mirum Pharmaceuticals, Inc. v. Zenara Pharma Private Limited - 1:25-cv-01539

Mirum Pharmaceuticals, Inc. v. Zenara Pharma Private Limited (Case No. 1:25-cv-01539), filed on Dec 19, 2025 in the District Court, D. Delaware involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:25-cv-01539
Filing Date
Dec 19, 2025
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. Delaware
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Satiogen Pharmaceuticals, Inc. -
Biophore India Pharmaceuticals Private Limited -
Shire Human Genetic Therapies, Inc. -
Zenara Pharma Private Limited -
Mirum Pharmaceuticals, Inc. -

Patents Involved

This case involves 8 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US10512657B2
-US11497745B2
-US11376251B2
-US11229647B2
-US11229661B2
-US11260053B2
-US12350267B2
-US11918578B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Dec 19, 2025Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mrr) (Entered: 12/19/2025)PACER Document
Dec 19, 2025COMPLAINT against Biophore India Pharmaceuticals Private Limited, Zenara Pharma Private Limited (Filing fee $ 405, receipt number ADEDC-4862730) - filed by Satiogen Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc., Shire Human Genetic Therapies, Inc. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Civil Cover Sheet)(mrr) (Entered: 12/19/2025)PACER Document
Dec 19, 2025Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Takeda Pharmaceuticals U.S.A. Inc. and Other Affiliates Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals International AG, Master Trust Bank of Japan, Ltd., and Takeda 2 Pharmaceutical Company Limited for Shire Human Genetic Therapies, Inc.; Corporate Parent Mirum Pharmaceuticals, Inc. for Satiogen Pharmaceuticals, Inc., filed by Mirum Pharmaceuticals, Inc., Satiogen Pharmaceuticals, Inc., Shire Human Genetic Therapies, Inc. (mrr) (Entered: 12/19/2025)PACER Document
Dec 19, 2025Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 10,512,657 B2; US 11,229,661 B2; US 12,350,267 B2; US 11,229,647 B2 ; US 11,376,251 B2; US 11,497,745 B2 ; US 11,918,578 B2; US 11,260,053 B2. (Attachments: # 1 Additional Patents)(mrr) (Entered: 12/19/2025)PACER Document
Dec 19, 2025Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 11/24/2025. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 3/29/2029. (mrr) (Entered: 12/19/2025)PACER Document
Dec 19, 2025Summons Issued as to Biophore India Pharmaceuticals Private Limited, Zenara Pharma Private Limited. (Attachments: # 1 Summons Issued)(mrr) (Entered: 12/19/2025)PACER Document
Dec 19, 2025CORRECTING ENTRY: The summons issued at D.I. 6 have been removed from the docket as they contained an error. The Clerk's Office will reissue the summons shortly. (nms)PACER Document
Dec 19, 2025CORRECTING ENTRY: Docket text for D.I. 3 has been amended to reflect the correct 30 month stay deadline. (mrr)PACER Document